

Ⅲ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
立俵良崇, 加藤規利, 丸山彰一	II. 各論 TMA	岡田浩一	最新ガイドラ インに基づく 腎・透析 診療	総合医学 社	日本	2021	235-242
森下英理 子	V 止血・血栓疾患 2) 先天性凝固因 子・凝固阻止因子 欠乏症/異常症	鈴木隆浩, 竹中克斗, 池添隆之	専門医のため の血液病学	医学書院	日本	2022	276-278
森下英理 子	播種性血管内凝 固症候群 (DIC)	福井次矢, 高木誠, 小 室一成	今日の治療指 針 2022	医学書院	日本	2022	718-721
長屋聡美, 森下英理 子	DIC モデル. モデ ル動物の作製と 利用	堀内久徳	循環器疾患 2021	エル・ア イ・シー	日本	2021	516-522

雑誌

発表者氏名	論文タイトル名	発表誌 名	巻号	ペー ジ	出版年
Nishikawa Y, Nishida S, Kuroda K, Kashiwagi H, Tomiyama Y, Kuwana M.	Development of an Automated Chemiluminescent Enzyme Immunoassay for Measuring Thrombopoietin in Human Plasma. Diagnostics	Diagnostics (Basel)	26	313	2022
Akuta K, Fukushima K, Nakata K, Hayashi S, Toda J, Shingai Y, Tsutsumi K, Machida T, Hino A, Kusakabe S, Doi Y, Fujita J, Kato H, Maeda T, Yokota T, Tomiyama Y, Hosen N, Kashiwagi H.	Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies.	Int J Hematol	115	322-328	2022

Ozaki Y, Wakui M, Fujimori Y, Oka S, Nakamura S, Kondo Y, Nakagawa T, Katagiri H, <u>Murata M</u>	In vitro unexpected effects of polyphosphates observed through activated partial thromboplastin time-based clot waveform analysis.	Int J Lab Hematol	43(4)	234-237	2021
Wakui M, Fujimori Y, Nakamura S, Oka S, Ozaki Y, Kondo Y, Nakagawa T, Katagiri H, <u>Murata M</u>	Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors.	J Clin Pathol	74(4)	251-256	2021
村田満	シリーズ スペシャリストの視点-血栓止血 (村田満) 第1回 AZ 製新型コロナウイルス副反応の血栓症に推奨の検査・治療	m3.com		https://www.m3.com/clinical/news/988848	2021
Sakai K, Wada H, Nakatsuka Y, Kubo M, Hayakawa M, <u>Matsumoto M.</u>	Characteristics behaviors of coagulation and fibrinolysis markers in acquired thrombotic thrombocytopenic purpura.	J Intensive Care Med.	36	436-442	2021
Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lämmle B, <u>Matsumoto M</u> , Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas M, Tomiyama Y, Veyradier A, Westwood JP, Scully M.	Redefining outcomes in immune TTP: an international working group consensus report.	Blood.	137(14)	1855-1861	2021
Tarasco E, Lukas Bütikofer L, Friedman KD, George JN, Hrachovinova IV, Knöbl P, <u>Matsumoto M</u> , von Krogh AS, Aebi-Huber I, Cermakova Z, Górska-Kosicka M, Jalowiec KA, Largiadèr CR, Prohaszka Z, Sinkovits G, Windyga J, Lämmle B, Kremer Hovinga JA.	Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura.	Blood.	137(25)	3563-3575	2021

Sakai K, Fujimura Y, Miyata T, Isonishi A, Kokame K, <u>Matsumoto M.</u>	Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort.	Br J Haematol.	194(2)	444-452	2021
Kayashima M, Sakai K, Harada K, Kanetake J, Kubo M, Hamada E, Hayakawa M, Hatakeyama K, <u>Matsumoto M.</u>	Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune thrombotic thrombocytopenic purpura.	Int J Hematol	114(4)	415-423	2021
Yoshida K, Sakaki A, Matsuyama Y, Mushino T, <u>Matsumoto M</u> , Sonoki T, Tamura S.	Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient.	Int Med	61(3)	407-412	2022
Hamada E, Sakai K, Yamada S, Kubo M, Hayakawa M, <u>Matsumoto M.</u>	No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey.	Ann Hematol			2022
Uchino K, Sakai K, Shinohara S, Matsuhisa A, Iida Y, Nakano Y, Matsumura S, Kanasugi J, Takasugi S, Nakamura A, Horio T, Murakami S, Mizuno S, Yamamoto H, Hanamura I, <u>Matsumoto M</u> , Takami A.	Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature.	Int J Hematol			2022
酒井和哉, <u>松本雅則</u>	【指定難病に見る出血・凝固の異常-病態研究と診療】血栓性血小板減少性紫斑病(指定難病 64)	Thrombosis Medicine	11(1)	12-18	2021
<u>松本雅則</u>	Hemolytic Anemia :Molecular Pathogenesis and New Treatment 血栓性血小板減少性紫斑病の病因と有望な新規治療薬	臨床血液	62(5)	480-485	2021

酒井和哉, <u>松本雅則</u>	【HLA 関連疾患】HLA と血栓性血小板減少性紫斑病(TTP)	臨床免疫・アレルギー科	75(5)	558-564	2021
酒井和哉, <u>松本雅則</u> , <u>桑名正隆</u> , <u>田中秀則</u> , <u>細道一善</u> .	日本人における免疫原性血栓性血小板減少性紫斑病の疾患感受性 HLA の網羅的解析	奈良県医師会医学年報	34(1)	64-70	2021
梶田樹矢, 小川孔幸, 松本 彬, 内藤千晶, 三原正大, 石川哲也, 小林宣彦, 宮澤悠里, 石崎卓馬, 清水立矢, 酒井和哉, 早川正樹, <u>松本雅則</u> , 半田 寛.	多発性脳梗塞を合併した難治性血栓性血小板減少性紫斑病	臨床血液	63(1)	55-61	2022
久保政之, <u>松本雅則</u>	【救急医もちゃんと知っておきたい 出血性疾患・血小板数低下疾患】血小板数低下を伴う血栓性疾患・病態 血栓性血小板減少性紫斑病/溶血性尿毒症症候群/非典型溶血性尿毒症症候群	救急医学	46(2)	151-160	2022
加藤規利, 立俵良崇, <u>丸山彰一</u>	腎臓医が診る指定難病 遺伝性腎疾患 飛天系溶血性尿毒症症候群(aHUS)/血栓性血小板減少性紫斑病(TTP)	腎と透析	91(1)	94-102	2021
Barbour T, Yoshitaka Miyakawa Y, et al.	Long-Term Efficacy and Safety of the Long Acting C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults	Kidney International Reports	6	1603-1613	2021
<u>宮川義隆</u>	COVID-19 関連凝固異常症、血栓性血小板減少性紫斑病、Xa 因子阻害薬に対する特異的中和薬	日本内科学会誌	110	2477-2484	2021
Osada M, Maruyama K, <u>Kokame K</u> , Denda R, Yamazaki K, Kunieda H, Hirao M, Madoiwa S, Okumura N, <u>Murata M</u> , Ikeda Y, Watanabe K, Tsukada Y, Kikuchi T	A novel homozygous variant of the thrombomodulin gene causes a hereditary bleeding disorder	Blood Adv	5(19)	3830-3838	2021
Watanabe A, Hataida H, Inoue N, Kamon K, Baba K, Sasaki K, Kimura R, Sasaki H, Eura Y, Ni WF, Shibasaki Y, Waguri S, <u>Kokame K</u> , Shiba Y	Arf GTPase-activating proteins SMAP1 and AGFG2 regulate the size of Weibel-Palade bodies and exocytosis of von Willebrand factor	Biol Open	10(9)	bio058789	2021

Eura Y, <u>Kokame K</u>	Commonly used anti-von Willebrand factor antibody for multimer analysis cross-reacts with fibronectin, which is difficult to distinguish from von Willebrand factor	Res Pract Thromb Haemost	5(6)	e12598	2021
Yamazaki Y, Eura Y, <u>Kokame K</u>	V-ATPase V0a1 promotes Weibel-Palade body biogenesis through the regulation of membrane fission	Elife	10	e71526	2021
Nagaya S, Maruyama K, Watanabe A, Meguro-Horike M, Imai Y, Hiroshima Y, Horike SI, <u>Kokame K</u> , Morishita E	First report of inherited protein S deficiency caused by paternal PROS1 mosaicism	Haematologica	107(1)	330-333	2022
丸山慶子, <u>小亀浩市</u>	公開データベースと発現実験を用いたアンチトロンビン、プロテインCおよびプロテインS遺伝子の病的バリエーションの頻度推定	日本血栓止血誌	32(5)	635-637	2021
<u>横山健次</u>	ITP の治療	臨床血液	62	1229-1235	2021
<u>大賀正一</u>	新生児・小児領域のゲノム医療	日本内科学会雑誌	98	102-103	2021
小林隆夫、 <u>森下英理子</u> 、津田博子、 <u>根木玲子</u> 、小嶋哲人、 <u>大賀正二</u> 、落合正行、安達知子、宮田敏行	遺伝性血栓性素因患者の妊娠分娩管理に関する診療の手引き Q&A	日本産婦人科・新生児血液学会誌	30	5-54	2021
Yamaguchi K, Yisireyili M, Goto S, Cheng XW, Nakayama T, <u>Matsushita T</u> , Niwa T, Murohara T, Takeshita K.	Indoxyl Sulfate Activates NLRP3 Inflammasome to Induce Cardiac Contractile Dysfunction Accompanied by Myocardial Fibrosis and Hypertrophy	Cardiovascular Toxicology	Epub 2022 Jan	-	2022
<u>Matsushita T</u> , Suzuki N, Nagao A, Nagae C, Yamaguchi-Suita H, Kyogoku Y, Ioka A, Nogami K	AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.	BMJ Open.	12(3)	e057018	2022

Odaira K, Kawashima F, Tamura S, Suzuki N, Tokoro M, Hayakawa Y, Suzuki A, Kanematsu T, Okamoto S, Takagi A, Katsumi A, <u>Matsushita T</u> , Shima M, Nogami K, Kojima T, Hayakawa F.	F9 mRNA splicing aberration due to a deep Intronic structural variation in a patient with moderate hemophilia B	Thromb Res.	Mar 15;213	91-96	2022
Tamura S, Mukaide M, Katsuragi Y, Fujii W, Odaira K, Suzuki N, Tsukiji N, Okamoto S, Suzuki A, Kanematsu T, Katsumi A, Takagi A, Ikeda K, Ueyama J, Hirayama M, Suzuki-Inoue K, <u>Matsushita T</u> , Kojima T, Hayakawa F.	Periosteum-derived podoplanin-expressing stromal cells regulate nascent vascularization during epiphyseal marrow development.	J Biol Chem.	2022 Mar 15	101833	2022
Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, Jiménez-Yuste V, Kavakli K, <u>Matsushita T</u> , Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J, Chowdary P	Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.	Blood Adv	2022 Mar 15	Online ahead of print	2022
Okada K, Tamura S, Suzuki N, Odaira K, Mukaide M, Fujii W, Katsuragi Y, Suzuki A, Kanematsu T, Okamoto S, Suzuki N, Katsumi A, <u>Matsushita T</u> , Kojima T, Hayakawa F	Protein S-Leu17Pro disrupts the hydrophobicity of its signal peptide causing a proteasome-dependent degradation.	Thromb Res	210	26-32	2022
Ogiwara K, Taki M, Suzuki T, Takedani H, <u>Matsushita T</u> , Amano K, <u>Matsumoto M</u> , Nishio K, Shima M, Kasahara M, Nogami	Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.	K. BMJ Open	12(2)	e056922	2022

Suzuki A, Suzuki N, Kanematsu T, Shinohara S, Kurono H, Arai N, Okamoto S, Suzuki N, Tamura S, Kikuchi R, Katsumi A, Kojima T, <u>Matsushita T.</u>	Development and validation of a novel qualitative test for plasma fibrinogen utilizing clot waveform analysis.	Sci Rep	12(1)	434	2022
Inukai Y, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, <u>Matsushita T,</u> Ishigami M, Fujishiro M.	The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophiliaHCC after HCV eradication in hemophilia.	Ann Hepatol	27(1)	100545	2022
Jiménez-Yuste V, Rodríguez-Merchán EC, <u>Matsushita T,</u> Holme PA	Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery.	Haemophil ia.	27(4)	519-530	2021
Katsumi A, Abe A, Tamura S, <u>Matsushita T</u>	Anemia in older adults as a geriatric syndrome: A review.	Geriatr Gerontol Int	21(7)	549-554	2021
Yamamoto T, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, <u>Matsushita T,</u> Ishigami M, Fujishiro M.	Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs.	Anticancer Res.	41(5)	2569-2573	2021
Hayakawa Y, Tamura S, Suzuki N, Odaira K, Tokoro M, Kawashima F, Hayakawa F, Takagi A, Katsumi A, Suzuki A, Okamoto S, Kanematsu T, <u>Matsushita T,</u> Kojima T.	Essential role of a carboxyl-terminal α -helix motif in the secretion of coagulation factor XI.	J Thromb Haemost.	19(4)	920-930	2021
Kobayashi T, <u>Morishita E,</u> Tsuda H, <u>Neki R,</u> Kojima T, <u>Ohga S,</u> Ochiai M, Adachi T, Miyata T.	Clinical guidance for peripartum management of patients with hereditary thrombophilia.	J Obstet Gynaecol Res	47	3008-3033	2021
<u>根木玲子</u>	妊娠中の治療量抗凝固療法について	日本血栓止血学会誌	32(5)	594-599	2021

Suga Y, Akita F, Yamada S, <u>Morishita E</u> , Asakura H.	Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide-induced disseminated intravascular coagulation in rats.	Biomed Rep	16(1)	5	2022
Yamada S, Arahata M, <u>Morishita E</u> , Asakura H.	Blue Rubber Bleb Nevus Syndrome Complicated by Enhanced-Fibrinolytic-Type DIC: A Case Report.	Ann Vasc Dis	14(3)	252-255	2021
Suga Y, Tashiro K, Staub Y, Komura S, Yamada S, <u>Morishita E</u> , Asakura H	Potential of continuous tPA infusion for multiple-organ failure from lipopolysaccharide-induced disseminated intravascular coagulation in rats	Thromb Res	206	84-87	2021
Suga Y, Kubo A, Katsura H, Staub Y, Tashiro K, Yamada S, <u>Morishita E</u> , Asakura H	Detailed exploration of pathophysiology involving inflammatory status and bleeding symptoms between lipopolysaccharide- and tissue factor-induced disseminated intravascular coagulation in rats.	Int J Hematol	114(2)	172-178	2021
Terakami T, Nagaya S, Hayashi K, Furusho H, Fujino N, Kato T, Asakura H, <u>Morishita E</u> .	Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors.	J Atheroscler Thromb	2021 Jul 30	doi: 10.5551/jat.62951.	2021
Suga Y, Takahashi Y, Shimada T, Yamada S, <u>Morishita E</u> , Asakura H	Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model.	In Vivo	35(4)	1999-2004	2021
Fukushima T, Shimomura Y, Nagaya S, <u>Morishita E</u> , Kawakami O	A Case of Treatment With Dabigatran for Cerebral Venous Thrombosis Caused by Hereditary Protein C Deficiency.	Cureus	13(6)	e15473	2021

Nangaku M, Kadowaki T, Yotsuyanagi H, Ohmagari N, Egi M, Sasaki J, Sakamoto T, Hasegawa Y, Ogura T, Chiba S, Node K, Suzuki R, Yamaguchi Y, Murashima A, Ikeda N, <u>Morishita E</u> , Yuzawa K, Moriuchi H, Hayakawa S, Nishi D, Irisawa A, Miyamoto T, Suzuki H, Sone H, Fujino Y	The Japanese Medical Science Federation COVID-19 Expert Opinion English Version.	JMA Journal	4(2)	148-162	2021
Kanosue K, Nagaya S, <u>Morishita E</u> , Yamanishi M, Imashuku S	Protein C Gene Mutation in an Older Adult Patient with Clostridium perfringens Septicemia-Related Visceral Vein Thrombosis.	TH Open	5(2)	e171-e173	2021
Ieko M, Hotta T, Watanabe K, Adachi T, Takeuchi S, Naito S, Yoshida M, Ohmura K, Takahashi N, <u>Morishita E</u> , Tsuda H, Kang D	Comparative evaluation of reagents for measuring protein S activity: possibility of harmonization.	Int J Hematol	113(4)	530-536	2021
高附磨理, 安本篤史, <u>森下英理子</u> , 他	ChAdOx-1 nCoV-19ワクチン接種後に血小板減少を伴う血栓症を発症した一例	臨床神経	62(6)	accept	2022
菅 幸生, スタッフ由紀子, 田代精亨, 山田真也, <u>森下英理子</u> , 朝倉英策	LPS誘発DICモデルに対するtPA投与による臓器障害の改善	日本検査血液学会雑誌	22(2)	178-184	2021
橋本洋一郎, 平野照之, <u>森下英理子</u> , 板橋亮, 安本篤史	ROUND TABLE DISCUSSION: COVID-19 ワクチンと血栓症 (TTS)	Cardio-Coagulation	9(1)	6-14	2022
<u>森下英理子</u>	炎症・免疫機序による血栓止血のトピックス⑤ 特発性血小板減少性紫斑病	炎症と免疫	30(2)	66-71	2022
<u>森下英理子</u>	抗血栓療法 (COVID-19関連血栓症)	腎と透析	92(1)	180-183	2022
長屋聡美, <u>森下英理子</u>	FOCUS 妊娠時の凝固・線溶系因子および分子マーカーの変動	検査と技術	50(1)	20-23	2022
<u>森下英理子</u>	【基礎と臨床の両面から挑む血栓止血学】COVID-19に伴う血栓症	医学のあゆみ	279(11)	1090-1095	2021
<u>森下英理子</u>	COVID-19関連凝固異常	日本検査血液学会雑誌	22(3)	379-388	2021

板橋 亮, 河野浩之, 坂井信幸, 中川一郎, 平野照之, 伊藤隆史, 射場敏明, 土井洋平, 森下英理子, 安本篤史, 日本脳卒中学会, 日本血栓止血学会, 2学会合同手引き作成委員会	アストラゼネカ社COVID-19ワクチン接種後の血小板減少症を伴う血栓症の診断と治療の手引き(第2版)	日本血栓止血学会誌	32(5)	S1-S25	2021
森下英理子	COVID-19関連凝固異常	臨床血液	62(8)	1236-1246	2021
日笠 聡, 渥美達也, 石黒 精, 金子 誠, 高橋芳右, 野上恵嗣, 藤井輝久, 堀内久徳, 松井太衛, 毛利 博, 森下英理子, 松下 正, 朝比奈俊彦, 天野景裕, 上田恭典, 岡本好司, 小亀浩市, 佐道俊幸, 瀧 正志, 長尾 梓, 西尾健治, 西田恭治, 西野正人, 藤村吉博, 松本雅則, 宮川義隆, 八木秀男, 和田 英 夫, von Willebrand病の診療ガイドライン作成委員会	von Willebrand病の診療ガイドライン 2021年版	日本血栓止血学会誌	32(4)	413-481	2021
森下英理子	COVID-19に伴う血栓症	臨床と研究	98(7)	845-852	2021
森下英理子	炎症・免疫機序による血栓止血のトピックス COVID-19関連凝固異常	炎症と免疫	29(4)	360-368	2021
堀内久徳, 森下英理子, 浦野哲盟, 横山健次	COVID-19関連血栓症アンケート調査の最終結果報告	日本血栓止血学会誌	32(3)	315-329	2021
堀内久徳, 森下英理子, 浦野哲盟, 横山健次	厚生労働省難治性疾患政策研究事業「血液凝固異常症等に関する研究」班. COVID-19関連血栓症アンケート調査結果報告	日本血栓止血学会誌	32(2)	205-205	2021